HY-19313-25mg
|
MedChemexpress LLC
|
LLY-507 [CAS 1793053-37-8]
|
|
Cancer-programmed cell death
|
|
HY-19313-5mg
|
MedChemexpress LLC
|
LLY-507 [CAS 1793053-37-8]
|
|
Cancer-programmed cell death
|
|
HY-19313-50mg
|
MedChemexpress LLC
|
LLY-507 [CAS 1793053-37-8]
|
|
Cancer-programmed cell death
|
|
HY-19313-1mL
|
MedChemexpress LLC
|
LLY-507 [CAS 1793053-37-8] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
HY-P1205A-10mg
|
MedChemexpress LLC
|
MCH(human, mouse, rat) (TFA)
|
|
Neuroscience-Neuromodulation
|
|
HY-P1205A-5mg
|
MedChemexpress LLC
|
MCH(human, mouse, rat) (TFA)
|
|
Neuroscience-Neuromodulation
|
|
HY-12220A-10mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-2mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-5mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-50mg
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5]
|
|
Cancer-programmed cell death
|
|
HY-12220A-1mL
|
MedChemexpress LLC
|
MM-102 (TFA) [CAS 1883545-52-5] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|